Cost-Effectiveness of the Implantable Cardioverter Defibrillator Mark A. HlatkyGillian D. SandersDouglas K. Owens OriginalPaper Pages: 479 - 482
Clinical Significance of Device-Related Complications in Clinical Trials and Implications for Future Trials: Insights from the Antiarrhytmics versus Implantable Defibrillators (AVID) Trial Jack Kron OriginalPaper Pages: 473 - 478
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: Rationale, Design, Results, Clinical Implications and Lessons for Future Trials Bruce L. Wilkoffthe DAVID Trial Investigators OriginalPaper Pages: 468 - 472
Clinical Trials of Prophylactic Implantable Defibrillator Therapy in Patients with Nonischemic Cardiomyopathy: What have We Learned and What can We Expect from Future Trials? Wolfram Grimm OriginalPaper Pages: 463 - 467
DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Andi SchaechterAlan H. Kadish OriginalPaper Pages: 457 - 462
Amiodarone versus Implantable Defibrillator (AMIOVIRT): Background, Rationale, Design, Methods, Results and Implications Mevan WijetungaS. Adam Strickberger OriginalPaper Pages: 452 - 456
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims Gerian GrönefeldStuart J. ConnollyStefan H. Hohnloser OriginalPaper Pages: 447 - 451
Using the MADIT II Criteria for Implantable Cardioverter Defibrillators—What is the Role of the Food and Drug Administration Approval? Helen S. Barold OriginalPaper Pages: 443 - 446
Enhancing Specificity Without Sacrificing Sensitivity: Potential Benefits of Using Microvolt T-Wave Alternans Testing to Risk Stratify the MADIT-II Population Richard J. Cohen OriginalPaper Pages: 438 - 442
Risk Stratification for Sudden Death: Do We Need Anything More Than Ejection Fraction? Alfred E. Buxton OriginalPaper Pages: 434 - 437
Cardiac Resynchronization Therapy with or without an Implantable Defibrillator: Only Indicated When Everything Else has Failed? J. GhoshGerry KayeJ.G.F. Cleland OriginalPaper Pages: 421 - 429
Pacing for Vasovagal Syncope After the Second Vasovagal Pacemaker Study (VPS II): A Matter of Judgement Geoffrey M. TrimAndrew D. KrahnRaymond Yee OriginalPaper Pages: 416 - 420
Second Vasovagal Pacemaker Study (VPS II): Rationale, Design, Results, and Implications for Practice and Future Clinical Trials Robert SheldonStuart Connolly OriginalPaper Pages: 411 - 415
Selecting the Appropriate Pacing Mode for Patients with Sick Sinus Syndrome: Evidence from Randomized Clinical Trials A.E. AlbertsenJ.C. Nielsen OriginalPaper Pages: 406 - 410
Relationships between Pacing Mode and Quality of Life: Evidence from Randomized Clinical Trials David Newman OriginalPaper Pages: 401 - 405
Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future Michael H. KimRichard G. TrohmanKim A. Eagle OriginalPaper Pages: 397 - 400
Cardioversion Related Thromboembolism: Value of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation Karlheinz SeidlJochen Senges OriginalPaper Pages: 392 - 396
Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation: ACUTE Trial Update Craig R. AsherAllan L. Klein OriginalPaper Pages: 387 - 391
Use of Subcutaneous Enoxaparin Compared to Intravenous Heparin and Oral Phenprocoumon in the Setting of Cardioversion—The ACE Study (Anticoagulation in Cardioversion Using Enoxaparin) Christoph StellbrinkUwe NixdorffJan-André Schmidt-Lucke OriginalPaper Pages: 382 - 386
Do Anticoagulation Management Services Improve Care? Implications of the Managing Anticoagulation Services Trial David B. Matchar OriginalPaper Pages: 379 - 381
Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in Carl van WalravenRobert G. HartStuart Connolly OriginalPaper Pages: 374 - 378
Aspirin—Anticoagulant Combination in Patients with Non Valvular Atrial Fibrillation Commentary on the FFAACS Study Results Philippe P. Lechat OriginalPaper Pages: 372 - 373
Atrial Fibrillation: Should we Target Platelets or the Coagulation Pathway? Kiat T. TanGregory Y.H. Lip OriginalPaper Pages: 370 - 371
AFFIRM and RACE Trials: Implications for the Management of Atrial Fibrillation Joseph L. BlackshearRobert E. Safford OriginalPaper Pages: 366 - 369
Does Sinus Rhythm Beget Sinus Rhythm? Effects of Prompt Cardioversion on the Frequency and Persistence of Recurrent Atrial Fibrillation Hung-Fat TseChu-Pak Lau OriginalPaper Pages: 359 - 365
Atrial Arrhythmia Burden as an Endpoint in Clinical Trials: Is it the Best Surrogate? Lessons from a Multicenter Defibrillator Trial David E. EulerPaul A. Friedman OriginalPaper Pages: 355 - 358
Does Rapid Atrial Pacing Terminate Atrial Fibrillation? A Comparison of Laboratory and Device Termination Studies Andrew R.J. MitchellNeil Sulke OriginalPaper Pages: 352 - 354
Efficacy of Atrial Antitachycardia Functions for Treating Atrial Fibrillation: Observations in Patients with a Dual-Chamber Defibrillator Renato RicciCarlo PignalberiMassimo Santini OriginalPaper Pages: 348 - 351
Atrial Pacing Therapies for Prevention of Atrial Fibrillation in Patients with Implantable Defibrillators Anne M. Gillis OriginalPaper Pages: 345 - 347
Effectiveness of Rapid Atrial Pacing for Termination of Drug Refractory Atrial Fibrillation: Results of a Dual Chamber Implantable Cardioverter Defibrillator Trial Michael R. GoldRobert B. LemanDavid E. Euler OriginalPaper Pages: 341 - 344
Detection of Atrial Fibrillation by Permanent Pacemakers: Observations from the STOP AF Trial C.J. PlummerJ.M. McComb OriginalPaper Pages: 333 - 340
Multisite Atrial Pacing for Atrial Fibrillation Prevention: Where to Go from Here? Anand Ramdat MisierWillem P. BeukemaRoger Willems OriginalPaper Pages: 329 - 332
Is Bachmann's Bundle the Only Right Site for Single-Site Pacing to Prevent Atrial Fibrillation? Results of a Multicenter Randomized Trial Steven J. Bailin OriginalPaper Pages: 325 - 328
Comparison of Permanent Left Ventricular and Biventricular Pacing in Patients with Heart Failure and Chronic Atrial Fibrillation: A Prospective Hemodynamic Study Stephane GarriguePierre BordacharJacques Clementy OriginalPaper Pages: 315 - 324
Selection of Pacing Mode after Interruption of Atrioventricular Conduction for Atrial Fibrillation: Observations from the PA3 Clinical Trial Anne M. Gillis OriginalPaper Pages: 312 - 314
Editorial: The Future of Cardiac Electrophysiology Review Kelley P. Anderson Editorial Introduction Pages: 311 - 311
Facilitating Electrical Cardioversion of Persistant Atrial Fibrillation by Antiarrhythmic Drugs: Update on Clinical Trial Results Ruey J. Sung OriginalPaper Pages: 300 - 303
Amiodarone for the Restoration of Sinus Rhythm in Patients with Atrial Fibrillation Panos E. VardasGeorge E. Kochiadakis OriginalPaper Pages: 297 - 299
Effect of Electrode Position on the Outcome of Cardioversion Paulus KirchhofMartin BorggrefeGünter Breithardt OriginalPaper Pages: 292 - 296
Biphasic Versus Monophasic Shock Waveform for Conversion of Atrial Fibrillation Robert W. RhoRichard L. Page OriginalPaper Pages: 290 - 291
An Update on Electrical Cardioversion of Atrial Fibrillation Suneet MittalKenneth M. SteinBruce B. Lerman OriginalPaper Pages: 285 - 289
Time to First Recurrence as a Trial Endpoint: Time to Change? Rahul Mehra OriginalPaper Pages: 280 - 284
Quality of Life Variables in the Selection of Rate Versus Rhythm Control in Patients with Atrial Fibrillation: Observations from the Canadian Trial of Atrial Fibrillation Paul DorianIqwal Mangat OriginalPaper Pages: 276 - 279
How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) John WikstrandHans WedelFinn Waagstein OriginalPaper Pages: 264 - 275
Antiarrhythmic Surgery to Cure Atrial Fibrillation—Subgroups and Postoperative Management Thomas DenekeKrishna KhargiBernd Lemke OriginalPaper Pages: 259 - 263
Left Versus Bi-Atrial Intraoperative Saline-Irrigated Radiofrequency Modified Maze Procedure for Atrial Fibrillation Mustafa GudenBelhhan AkpinarSeher Deniz Oztekin OriginalPaper Pages: 252 - 258
Conducting Randomized Trials in the Electrophysiology Laboratory: Lessons from a Randomized Comparison of Recording Methods During Pulmonary Vein Isolation by Segmental Ostial Ablation Hakan OralFred Morady OriginalPaper Pages: 247 - 251
Angiotensin Receptor Blocker as Adjunctive Therapy for Rhythm Control in Atrial Fibrillation: Results of the Irbesartan-Amiodarone Trial Antonio H. MadridCarlos EscobarConcepción Moro OriginalPaper Pages: 243 - 246
Role of Beta-Blocker Therapy in Heart Failure and Atrial Fibrillation Jeffrey W.H. FungCheuk M. YuJohn E. Sanderson OriginalPaper Pages: 236 - 242
